Astrazeneca AB has reported new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment covalently linked to cytotoxic drug potentially useful for the treatment of cancer.
Astrazeneca AB has reported new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment covalently linked to cytotoxic drug potentially useful for the treatment of cancer.